title: Novel compound heterozygous mutations for lipoprotein lipase deficiency. A G-to-T transversion at the first position of exon 5 causing G154V missense mutation and a 5' splice site mutation of intron 8.
abstract: We systematically investigated the molecular defects causing a primary LPL deficiency in a Japanese male infant (patient DI) with fasting hyperchylomicronemia (type I hyperlipoproteinemia) and in his parents. Patient DI had neither LPL activity nor immunoreactive LPL mass in the pre- and post-heparin plasma. The patient was a compound heterozygote for novel mutations consisting of a G-to-T transversion at the first nucleotide of exon 5 [+1 position of 3' acceptor splice site (3'-ass) of intron 4] and a T-to-C transition in the invariant GT at position +2 of the 5' donor splice site (5'-dss) of intron 8 (Int8/5'-dss/t(+2)c). The G-to-T transversion, although affecting the 11 nucleotide of the 3'-consensus acceptor splice site, resulted in a substitution of Gly(154) to Val (G154V; GG(716)C(-->)GTC). The mutant G154V LPL expressed in COS-1 cells was catalytically inactive and hardly released from the cells by heparin. The Int8/5'-dss/t(+2)c mutation inactivated the authentic 5' splice site of intron 8 and led to the utilization of a cryptic 5'-dss in exon 8 as an alternative splice site 133 basepairs upstream from the authentic splice site, thereby causing joining of a part of exon 8 to exon 9 with skipping of a 134-bp fragment of exon 8 and intron 8. These additional mutations in the consensus sequences of the 3' and 5' splice sites might be useful for better understanding the factors that are involved in splice site selection in vivo.
authors.affiliation: Departments of Etiology and Pathophysiology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. yikeda@ri.ncvc.go.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: A
authors.initials: A
authors.lastname: Takagi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakata
authors.forename: Y
authors.initials: Y
authors.lastname: Sera
authors.forename: S
authors.initials: S
authors.lastname: Hyoudou
authors.forename: K
authors.initials: K
authors.lastname: Hamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Nishi
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D001483:Base Sequence; D019556:COS Cells; D002675:Child, Preschool; D018076:DNA, Complementary / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005260:Female; D005796:Genes / Q000235:genetics; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000235:genetics*; D015228:Hypertriglyceridemia / Q000209:etiology / Q000235:genetics*; D007223:Infant; D007438:Introns / Q000235:genetics; D007564:Japan; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D020125:Mutation, Missense / Q000235:genetics* / Q000502:physiology; D022821:RNA Splice Sites / Q000235:genetics*
chemical_list: D018076:DNA, Complementary; D022821:RNA Splice Sites; D008049:Lipase; D008071:Lipoprotein Lipase